Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Research Articles

Nuclear factor κB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos

Borbala Daroczi, Gabor Kari, Qing Ren, Adam P. Dicker and Ulrich Rodeck
Borbala Daroczi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabor Kari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qing Ren
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam P. Dicker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Rodeck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-09-0198 Published September 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Effects of the proteasome inhibitors PS-341 (A), MG132 (B), and lactacystin (C) on the radiation sensitivity of zebrafish embryos. Embryos were irradiated at 24 hpf and survival was scored every day up to 7 dpf. Results shown represent mean ± SD of triplicate experiments. *, statistically significant difference in survival at 6 to 7 dpf.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Protection against and mitigation of lethal effects of radiation by direct NF-κB inhibitors. Differential survival of zebrafish embryos pretreated with EP (A and C) or CDDO-TFEA (B and D) and exposed to either 20 or 40 Gy as indicated. E, radiation protection of zebrafish embryos exposed to 20 Gy and treated for 1 h prior to irradiation with different IKK inhibitors. F, increased survival of irradiated (20 Gy) zebrafish embryos treated with EP (1mmol/L) or CDDO-TFEA (1 μmol/L) 2 h post radiation at 24 hpf. Survival was scored at 7 dpf. All results shown represent mean ± SD of triplicate experiments. *, statistically significant differences in survival at 7 dpf between drug-treated and vehicle-treated groups.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Reduction of organism-wide apoptosis by EP and CDDO-TFEA treatment preradiation and postradiation. Acridine orange (AO) staining of whole embryos was done 6 h postradiation at 30 hpf. A, representative examples of control or irradiated fish revealing strong AO staining in the central nervous system and along the body axis induced by radiation (20 Gy). Regions selected for quantitative evaluation are boxed. B, reduced AO staining in CDDO-TFEA- and EP-treated embryos exposed to ionizing radiation. C, PS-341 or MG132 treatment does not significantly affect AO staining of embryos exposed to ionizing radiation.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Effects of EP and CDDO-TFEA on radiation-induced kidney damage as determined by dextran clearance. A, Representative images of dextran retention in irradiated embryos and effects of EP and CDDO-TFEA on this phenomenon. B, quantitative representation of dextran retention in embryos treated with either EP or CDDO-TFEA as indicated; results are expressed relative to vehicle-treated, nonirradiated controls. *, statistically significant differences between the experimental groups indicated by brackets.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    EP and CDDO-TFEA alleviate radiation-induced malformations of the body axis. A, representative micrographs showing dorsal curvature (“curly-up”; cup) in irradiated (20 Gy) embryos at 72 hpf relative to control nonirradiated fish embryos. B, quantification of curly-up incidence in CDDO-TFEA- and EP-treated fish relative to vehicle-treated controls. *, statistically significant differences between the experimental groups indicated by brackets.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Effects of EP and CDDO-TFEA on radiation-induced alterations of the gastrointestinal system. A, improved PLA2 activity and gastrointestinal lumen formation in irradiated zebrafish treated with either EP or CDDO-TFEA. Dequenched fluorescence reflects endogenous PLA2 activity and transport of cleavage products through the lumen of the developing gastrointestinal system. B, quantitative evaluation of gastrointestinal lumen formation as determined by fluorescent dye content at 6 dpf. C, representative histologic sections of hindgut proximal to the cloaca at 6 dpf [5 d post (12 Gy)].

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Data
PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (9)
September 2009
Volume 8, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Nuclear factor κB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
Citation Tools
Nuclear factor κB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos
Borbala Daroczi, Gabor Kari, Qing Ren, Adam P. Dicker and Ulrich Rodeck
Mol Cancer Ther September 1 2009 (8) (9) 2625-2634; DOI: 10.1158/1535-7163.MCT-09-0198

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nuclear factor κB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos
Borbala Daroczi, Gabor Kari, Qing Ren, Adam P. Dicker and Ulrich Rodeck
Mol Cancer Ther September 1 2009 (8) (9) 2625-2634; DOI: 10.1158/1535-7163.MCT-09-0198
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Sorafenib Enhances Regional Chemotherapy in Melanoma
  • G1 Arrest by Ascofuranone
  • HPV-16 and Transcriptional Gene Silencing
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement